Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.
Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network. Kwiatkowski JL, et al. Among authors: mueller bu. Blood. 2012 Mar 22;119(12):2746-53. doi: 10.1182/blood-2011-04-344507. Epub 2012 Jan 25. Blood. 2012. PMID: 22279056 Free PMC article.
Hemoglobin H-constant spring in North America: an alpha thalassemia with frequent complications.
Singer ST, Kim HY, Olivieri NF, Kwiatkowski JL, Coates TD, Carson S, Neufeld E, Cunningham MJ, Giardina PJ, Mueller BU, Quinn CT, Fung E, Vichinsky E; Thalassemia Clinical Research Network. Singer ST, et al. Among authors: mueller bu. Am J Hematol. 2009 Nov;84(11):759-61. doi: 10.1002/ajh.21523. Am J Hematol. 2009. PMID: 19787795 Free PMC article.
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cell Investigators. Vichinsky E, et al. Among authors: mueller bu. Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x. Br J Haematol. 2007. PMID: 17233848 Free PMC article. Clinical Trial.
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF. Vichinsky E, et al. Among authors: mueller bu. Acta Haematol. 2008;119(3):133-41. doi: 10.1159/000125550. Epub 2008 Apr 11. Acta Haematol. 2008. PMID: 18408362 Clinical Trial.
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.
Helton KJ, Adams RJ, Kesler KL, Lockhart A, Aygun B, Driscoll C, Heeney MM, Jackson SM, Krishnamurti L, Miller ST, Sarnaik SA, Schultz WH, Ware RE; SWiTCH Investigators. Helton KJ, et al. Blood. 2014 Aug 7;124(6):891-8. doi: 10.1182/blood-2013-12-545186. Epub 2014 Jun 9. Blood. 2014. PMID: 24914136 Free PMC article. Clinical Trial.
Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia.
Wang ZJ, Fischer R, Chu Z, Mahoney DH Jr, Mueller BU, Muthupillai R, James EB, Krishnamurthy R, Chung T, Padua E, Vichinsky E, Harmatz P. Wang ZJ, et al. Among authors: mueller bu. Magn Reson Imaging. 2010 Apr;28(3):363-71. doi: 10.1016/j.mri.2009.12.001. Epub 2010 Jan 12. Magn Reson Imaging. 2010. PMID: 20061110 Free PMC article.
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Ware RE, Helms RW; SWiTCH Investigators. Ware RE, et al. Blood. 2012 Apr 26;119(17):3925-32. doi: 10.1182/blood-2011-11-392340. Epub 2012 Feb 7. Blood. 2012. PMID: 22318199 Free PMC article. Clinical Trial.
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.
Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ. Bennett CM, et al. Among authors: mueller bu. Blood. 2006 Apr 1;107(7):2639-42. doi: 10.1182/blood-2005-08-3518. Epub 2005 Dec 13. Blood. 2006. PMID: 16352811 Free PMC article. Clinical Trial.
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH). Alvarez O, et al. Among authors: mueller bu. Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30. Am J Hematol. 2013. PMID: 23861242 Free PMC article. Clinical Trial.
168 results